learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forLearn
1 / 1 resultsResearch
5 / 319 resultsresearch What's New in Therapy for Male Androgenetic Alopecia?
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
The mouse models are effective for testing new hair loss treatments.
research Androgen Receptor Modulators: A Review of Recent Patents and Reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
Community Join
5 / 318 resultscommunity Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Received Kintor’s KX-826 Today
A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.
community Reminder that Kintors Pyrilutamide results will be out this month
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Been on Min and Fin for Years and I am Devastated.
Guyman567 has been using oral finasteride and topical minoxidil for years but continues to experience hair loss and thinning, which has affected his confidence. He has tried various treatments including topical finasteride, microneedling, and vitamins, and is considering a hair transplant but is concerned about ongoing hair loss.